When baseline PD was used to divide each treatment group into
5- to 6-mm and 7- to 12-mm subgroups, no significant betweengroup
differences were found at any observed time (Table 4). Thepercentage of resolved sites (i.e., PD reduction ≥2 mm) in SRP+AP
(76.43%) and in SRP+PB (68.06%) was no significant differences
(Table 5)